Fulcrum Therapeutics, Inc.
FULCHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeFulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical. The company carries a $461.1M market cap, placing it firmly in the small-cap category. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Market Cap
$461.1M
Beta
3.01
P/E (TTM)
—
P/E (Fwd)
-5.21
EPS (TTM)
$-1.15
EPS (Fwd)
$-1.33
ROE
-27.1%
ROA
-18.4%
Cash
$333.3M
Total Debt
$5.9M
Free CF
-$37.7M
52W Change
-0.6%
Annual Financials
Cash vs Debt
With $333.3M in cash and $5.9M in debt, FULC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$37.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -27.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $6.3M (2022) to $0 (2025), a 100% decline worth watching.
Fulcrum Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing FULC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.